Alector Stock Price, News & Analysis (NASDAQ:ALEC) $6.12 +0.32 (+5.52%) (As of 12/8/2023 ET) Add Compare Share Share Today's Range$5.65▼$6.3950-Day Range$3.77▼$6.6852-Week Range$3.66▼$9.86Volume668,308 shsAverage Volume593,985 shsMarket Capitalization$514.91 millionP/E RatioN/ADividend YieldN/APrice Target$13.70 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Alector MarketRank™ Stock AnalysisAnalyst RatingHold2.44 Rating ScoreUpside/Downside123.9% Upside$13.70 Price TargetShort InterestBearish11.68% of Float Sold ShortDividend StrengthN/ASustainability-0.92Upright™ Environmental ScoreNews Sentiment-0.72Based on 4 Articles This WeekInsider TradingSelling Shares$3.19 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.78) to ($2.33) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.08 out of 5 starsMedical Sector443rd out of 954 stocksBiological Products, Except Diagnostic Industry50th out of 128 stocks 3.2 Analyst's Opinion Consensus RatingAlector has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on 5 buy ratings, 3 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.70, Alector has a forecasted upside of 123.9% from its current price of $6.12.Amount of Analyst CoverageAlector has only been the subject of 3 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted11.68% of the float of Alector has been sold short.Short Interest Ratio / Days to CoverAlector has a short interest ratio ("days to cover") of 10, which indicates bearish sentiment.Change versus previous monthShort interest in Alector has recently decreased by 6.90%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAlector does not currently pay a dividend.Dividend GrowthAlector does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAlector has received a 70.25% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for diseases with neurocognitive impairment" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Alector is -0.92. Previous Next 1.3 News and Social Media Coverage News SentimentAlector has a news sentiment score of -0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Alector this week, compared to 1 article on an average week.Search Interest1 people have searched for ALEC on MarketBeat in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alector insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,185,926.00 in company stock.Percentage Held by Insiders14.00% of the stock of Alector is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions69.71% of the stock of Alector is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Alector are expected to decrease in the coming year, from ($1.78) to ($2.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alector is -3.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alector is -3.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlector has a P/B Ratio of 2.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Alector Stock (NASDAQ:ALEC)Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its pipeline products include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001, AL002, and AL101 to treat neurodegenerative diseases. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.Read More ALEC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALEC Stock News HeadlinesDecember 1, 2023 | marketbeat.comThese biotechs targeting multiple neurodegenerative diseases (ALEC)A growing number of up-and-coming biotech firms are demonstrating the value of expanding a drug's total addressable market.December 8, 2023 | markets.businessinsider.comHold Rating on Alector Amid Potential for AL002 in Alzheimer’s, Caution Advised Pending Clinical DataDecember 8, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.November 8, 2023 | markets.businessinsider.comBuy Rating on Alector: Advancements in Neuro Pipeline, Operational Efficiency, and Anticipated Catalysts Drive Positive OutlookNovember 8, 2023 | finanznachrichten.deAlector, Inc.: Alector Reports Third Quarter 2023 Financial Results and Provides Business UpdateNovember 8, 2023 | finance.yahoo.comAlector to Participate in the Stifel Healthcare ConferenceNovember 7, 2023 | chron.comAlector: Q3 Earnings SnapshotNovember 7, 2023 | finance.yahoo.comAlector Reports Third Quarter 2023 Financial Results and Provides Business UpdateDecember 8, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.October 27, 2023 | msn.comAlector achieves target enrollment for Phase 3 dementia studyOctober 5, 2023 | markets.businessinsider.comAlector’s Financial Stability and Promising Clinical Developments: An Analyst’s Hold Rating RationaleOctober 4, 2023 | msn.comAlector: Milestone Uncertainty Plus Lack Of Product RevenueSeptember 25, 2023 | msn.comAlector slips as Goldman Sachs starts at Sell on risk to lead programsSeptember 25, 2023 | msn.comHigh Tide, Alector among healthcare moversSeptember 23, 2023 | msn.comCantor Fitzgerald Initiates Coverage of Alector (ALEC) with Overweight RecommendationSeptember 22, 2023 | benzinga.comAnalyst Expectations for Alector's FutureSeptember 9, 2023 | seekingalpha.comAlector completes enrollments in mid-stage Alzheimer’s trialSeptember 8, 2023 | msn.comAlector completes enrolment in AL002 trial to treat early Alzheimer’sAugust 31, 2023 | msn.comAlector (ALEC) Price Target Increased by 30.49% to 15.59August 12, 2023 | msn.comMizuho Maintains Alector (ALEC) Buy RecommendationAugust 10, 2023 | markets.businessinsider.comAlector (ALEC) Receives a Buy from Mizuho SecuritiesAugust 9, 2023 | msn.comStifel Maintains Alector (ALEC) Hold RecommendationAugust 8, 2023 | msn.comMorgan Stanley Reiterates Alector (ALEC) Equal-Weight RecommendationAugust 5, 2023 | msn.comHC Wainwright & Co. Reiterates Alector (ALEC) Buy RecommendationAugust 4, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for Alector (ALEC)August 4, 2023 | marketwatch.comAlector Up 31% After 2Q Results, Drug Program UpdateJuly 27, 2023 | finance.yahoo.comAlector to Host Mid-Year Earnings Conference CallSee More Headlines Receive ALEC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alector and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2023Today12/08/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/27/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALEC CUSIPN/A CIK1653087 Webwww.alector.com Phone(415) 231-5660FaxN/AEmployees246Year Founded2013Price Target and Rating Average Stock Price Target$13.70 High Stock Price Target$41.00 Low Stock Price Target$4.00 Potential Upside/Downside+123.9%Consensus RatingHold Rating Score (0-4)2.44 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($1.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-133,310,000.00 Net Margins-146.80% Pretax Margin-142.37% Return on Equity-74.78% Return on Assets-19.39% Debt Debt-to-Equity RatioN/A Current Ratio3.95 Quick Ratio3.95 Sales & Book Value Annual Sales$96.31 million Price / Sales5.35 Cash FlowN/A Price / Cash FlowN/A Book Value$2.59 per share Price / Book2.36Miscellaneous Outstanding Shares84,136,000Free Float72,357,000Market Cap$514.91 million OptionableNot Optionable Beta0.69 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Arnon Rosenthal Ph.D. (Age 67)Co-Founder, CEO & Director Comp: $1.02MDr. Sara Kenkare-Mitra Ph.D. (Age 55)President and Head of Research & Development Comp: $1.19MDr. Marc Grasso M.D. (Age 50)CFO, Principal Financial Officer & Principal Accounting Officer Comp: $738.05kDr. Gary Romano M.D. (Age 61)Ph.D., Chief Medical Officer Comp: $602.98kMr. Peter Heutink Ph.D.Chief Scientific OfficerKatie HoganSenior Director of Corporate Communication & Investor RelationsMs. Danielle Pasqualone J.D.Ph.D., General CounselMs. Clare Hunt M.B.A.Chief People OfficerMs. Kristina Cutter M.P.H.Chief Regulatory, Pharmacovigilance, & Quality Assurance OfficerMs. Virginia DeJesus-Rueff M.B.A.Chief of Staff & Head of StrategyMore ExecutivesKey Competitorsbluebird bioNASDAQ:BLUEAllogene TherapeuticsNASDAQ:ALLOCaribou BiosciencesNASDAQ:CRBUNantKwestNASDAQ:NKLexeo TherapeuticsNASDAQ:LXEOView All CompetitorsInsiders & InstitutionsArnon RosenthalSold 23,831 sharesTotal: $132,500.36 ($5.56/share)Gary RomanoSold 5,035 sharesTotal: $27,994.60 ($5.56/share)Marc GrassoSold 4,574 sharesTotal: $25,431.44 ($5.56/share)Euclidean Capital LLCBought 326,964 shares on 12/1/2023Ownership: 1.554%American Century Companies Inc.Sold 28,554 shares on 11/30/2023Ownership: 0.090%View All Insider TransactionsView All Institutional Transactions ALEC Stock Analysis - Frequently Asked Questions Should I buy or sell Alector stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alector in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" ALEC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALEC, but not buy additional shares or sell existing shares. View ALEC analyst ratings or view top-rated stocks. What is Alector's stock price target for 2024? 9 brokers have issued 1 year price objectives for Alector's stock. Their ALEC share price targets range from $4.00 to $41.00. On average, they anticipate the company's share price to reach $13.70 in the next twelve months. This suggests a possible upside of 123.9% from the stock's current price. View analysts price targets for ALEC or view top-rated stocks among Wall Street analysts. How have ALEC shares performed in 2023? Alector's stock was trading at $9.23 at the start of the year. Since then, ALEC shares have decreased by 33.7% and is now trading at $6.12. View the best growth stocks for 2023 here. Are investors shorting Alector? Alector saw a decrease in short interest during the month of November. As of November 15th, there was short interest totaling 7,150,000 shares, a decrease of 6.9% from the October 31st total of 7,680,000 shares. Based on an average daily trading volume, of 717,100 shares, the short-interest ratio is currently 10.0 days. Approximately 11.7% of the shares of the stock are sold short. View Alector's Short Interest. When is Alector's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024. View our ALEC earnings forecast. How were Alector's earnings last quarter? Alector, Inc. (NASDAQ:ALEC) issued its quarterly earnings results on Tuesday, November, 7th. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.12. The business had revenue of $9.11 million for the quarter, compared to analysts' expectations of $9 million. Alector had a negative net margin of 146.80% and a negative trailing twelve-month return on equity of 74.78%. What ETF holds Alector's stock ? iShares Neuroscience and Healthcare ETF holds 7,557 shares of ALEC stock, representing 1.22% of its portfolio. What is Arnon Rosenthal's approval rating as Alector's CEO? 4 employees have rated Alector Chief Executive Officer Arnon Rosenthal on Glassdoor.com. Arnon Rosenthal has an approval rating of 100% among the company's employees. This puts Arnon Rosenthal in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Alector own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alector investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Pfizer (PFE), Advanced Micro Devices (AMD), Gossamer Bio (GOSS), Kaleido Biosciences (KLDO), QUALCOMM (QCOM), Intel (INTC), Micron Technology (MU) and Cisco Systems (CSCO). When did Alector IPO? (ALEC) raised $177 million in an initial public offering on Thursday, February 7th 2019. The company issued 9,300,000 shares at $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays served as the underwriters for the IPO. Who are Alector's major shareholders? Alector's stock is owned by many different institutional and retail investors. Top institutional shareholders include FMR LLC (14.47%), Braidwell LP (4.84%), Morgan Stanley (3.97%), JPMorgan Chase & Co. (2.72%), Euclidean Capital LLC (1.55%) and Jacobs Levy Equity Management Inc. (0.92%). Insiders that own company stock include Arnon Rosenthal, Calvin Yu, Gary Romano, Marc Grasso, Polaris Venture Management Co, Richard H Scheller, Robert King, Robert Paul, Sara Kenkare-Mitra and Shehnaaz Suliman. View institutional ownership trends. How do I buy shares of Alector? Shares of ALEC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. Does Alector have any subsidiaries? The following companies are subsidiares of Alector: Alector LLC.Read More This page (NASDAQ:ALEC) was last updated on 12/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alector, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.